To assess the correlation between serum Golgi protein-73 (GP-73) and the degree of hepatic fibrosis in children with autoimmune liver diseases. This case–control study included 100 children. Group A involved 50 children with autoimmune hepatitis (AIH), aged 2–17 years (mean 11.3 ± 2.7 years), while Group B included 50 age- and sex-matched healthy controls. All participants underwent clinical assessment, abdominal ultrasonography, laboratory investigations, and measurement of serum GP-73 using enzyme-linked immunosorbent assay. Children with AIH had significantly higher serum GP-73 levels than controls (median 110.7 ng/L vs. 21.3 ng/L, p < 0.001). GP-73 levels showed a strong positive correlation with both the histological activity index (r = 0.879, p < 0.001) and the stage of fibrosis (r = 0.647, p < 0.001). At a cutoff level > 49 ng/L, GP-73 distinguished AIH cases with 100% sensitivity and 100% specificity. For identifying severe fibrosis, a cutoff > 124.6 ng/L yielded 100% sensitivity and 91.7% specificity (area under the ROC curve = 0.995, p < 0.001).Conclusion: Serum GP-73 levels are significantly elevated in children with autoimmune hepatitis and correlate strongly with both histological grading and staging. GP-73 may serve as a reliable non-invasive marker for assessing disease severity and guiding clinical management in pediatric autoimmune liver diseases.<Table Float="No" ID="Taba"> <tgroup cols="1"> <colspec align="left" colname="c1" colnum="1" /> <tbody> <row> <entry align="left" colname="c1"> What is Known: • Non-invasive biomarkers for assessing liver fibrosis in children with autoimmune hepatitis are still limited, and liver biopsy remains the gold standard despite its risks. </entry> </row> <row> <entry align="left" colname="c1"> What is New: • Serum GP-73 is significantly elevated in pediatric AIH, strongly correlates with fibrosis severity, and may serve as a reliable non-invasive biomarker. </entry> </row> </tbody> </tgroup> </Table>

Serum golgi protein-73 (GP-73) in children with autoimmune hepatitis

期刊论文
出版模式：

开放获取
发表日期：

2025年9月3日

查看全文

Marwa Sabry Rizk,
Ola Galal Ali Behairy,
Amera Mohamed Abdel Salam Dawood,
Rana Atef Khashaba,
Walaa El Gendy,
Nashwa Farouk Mohamed

摘要

To assess the correlation between serum Golgi protein-73 (GP-73) and the degree of hepatic fibrosis in children with autoimmune liver diseases. This case–control study included 100 children. Group A involved 50 children with autoimmune hepatitis (AIH), aged 2–17 years (mean 11.3 ± 2.7 years), while Group B included 50 age- and sex-matched healthy controls. All participants underwent clinical assessment, abdominal ultrasonography, laboratory investigations, and measurement of serum GP-73 using enzyme-linked immunosorbent assay. Children with AIH had significantly higher serum GP-73 levels than controls (median 110.7 ng/L vs. 21.3 ng/L, p < 0.001). GP-73 levels showed a strong positive correlation with both the histological activity index (r = 0.879, p < 0.001) and the stage of fibrosis (r = 0.647, p < 0.001). At a cutoff level > 49 ng/L, GP-73 distinguished AIH cases with 100% sensitivity and 100% specificity. For identifying severe fibrosis, a cutoff > 124.6 ng/L yielded 100% sensitivity and 91.7% specificity (area under the ROC curve = 0.995, p < 0.001).

Conclusion: Serum GP-73 levels are significantly elevated in children with autoimmune hepatitis and correlate strongly with both histological grading and staging. GP-73 may serve as a reliable non-invasive marker for assessing disease severity and guiding clinical management in pediatric autoimmune liver diseases.

What is Known:

• Non-invasive biomarkers for assessing liver fibrosis in children with autoimmune hepatitis are still limited, and liver biopsy remains the gold standard despite its risks.

What is New:

• Serum GP-73 is significantly elevated in pediatric AIH, strongly correlates with fibrosis severity, and may serve as a reliable non-invasive biomarker.